[Multidrug resistance].
The past decade has seen the successful application of genetic techniques in the dissection of the most important phenotypes of cancer cells. In the case of drug resistance mechanisms, the elucidation of the genes involved in resistance to anticancer agents has led to new and unexpected information about tumor physiology and may well open therapeutic options by virtue of reversing clinical chemoresistance. The experimental characterization of defined multidrug resistance factors, such as P-glycoprotein, multidrug resistance associated protein, topoisomerase, or glutathione-S-transferase in urologic malignancies, is now relatively comprehensive, allowing for an initial analysis. Clinical studies on some of these concepts have been started and will be the subject of careful scrutiny. We expect that they will have a considerable impact on the way certain urologic anticancer strategies will be pursued in the future.
Urologische Klinik, Klinikum Dijkzigt, Erasmus Universität Rotterdam.
G H
GH
Mickisch
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000235:genetics; D018528:ATP-Binding Cassette Transporters / Q000235:genetics; D002986:Clinical Trials as Topic; D004264:DNA Topoisomerases, Type I / Q000235:genetics; D018432:Drug Resistance, Multiple / Q000235:genetics*; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D015972:Gene Expression Regulation, Neoplastic / Q000502:physiology; D005982:Glutathione Transferase / Q000235:genetics; D006801:Humans; D027425:ATP-Binding Cassette, Sub-Family C Proteins; D014571:Urologic Neoplasms / Q000188:drug therapy* / Q000235:genetics*
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D018528:ATP-Binding Cassette Transporters; D004264:DNA Topoisomerases, Type I; D005982:Glutathione Transferase; D027425:ATP-Binding Cassette, Sub-Family C Proteins